The ethyl acetate fraction of corn silk exhibits dual antioxidant and anti-glycation activities and protects insulin-secreting cells from glucotoxicity by Chia-Chuan Chang et al.
RESEARCH ARTICLE Open Access
The ethyl acetate fraction of corn silk
exhibits dual antioxidant and anti-glycation
activities and protects insulin-secreting cells
from glucotoxicity
Chia-Chuan Chang1†, Wei Yuan2†, Hsiao-Yuh Roan3, Jia-Ling Chang4, Hsiu-Chen Huang5, Yu-Ching Lee6,7,
Huey Jen Tsay8 and Hui-Kang Liu4,9*
Abstract
Background: In this study, we aimed to develop a Stigmata Maydis (corn silk) fraction with dual bio-activities
against oxidative stress and protein glycation to protect β-cells from diabetes-induced failure.
Methods: Corn silk fractions were prepared by partition and chemically characterised by thin-layer
chromatography. Free radical scavenging assay, glycation assay, and cell-based viability test (neutral red) were
employed to decide the best fraction. Cell death analysis was executed by annexin V/ Propidium iodide staining.
Cell proliferation was measured by WST-1. Finally, β-cell function was evaluated by β-cell marker gene expression
(RT-PCR) and acute insulin secretion test.
Results: Four corn silk fractions were prepared from an ethanolic crude extract of corn silk. In vitro assays indicate
ethyl acetate fraction (YMS-EA) was the most potent fraction. YMS-EA also attenuated the hydrogen peroxide- or
methylglyoxal-induced induction of reactive oxygen species, reduction of cell viability, and inhibition of cell
proliferation. However, YMS-EA was unable to prevent hydrogen peroxide-induced apoptosis or advanced glycation
end-products-induced toxicity. Under hyperglycemic conditions, YMS-EA effectively reduced ROS levels, improved
mRNA expression of insulin, glucokinase, and PDX-1, and enhanced glucose-stimulated insulin secretion. The
similarity of bioactivities among apigenin, luteolin, and YMS-EA indicated that dual activities of YMS-EA might be
derived from those compounds.
Conclusions: We concluded that YMS-EA fraction could be developed as a preventive food agent against the
glucotoxicity to β-cells in Type 2 diabetes.
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Background
Maize is known as corn which is widely grown in the
Americas. In the United States alone, approximately 332
million metric tons of corn are grown annually [1]. Corn
silk (Stigmata Maydis) is the female part of the corn. Al-
though corn silk is often processed as agriculture waste, it
is actually consumed as tea or regarded as an herb in trad-
itional medicine. The main medicinal property of corn silk
is to promote fluid excretion and reduce swelling [2]. In
addition to its use as a natural diuretic, pharmacological
studies of corn silk revealed antioxidant and anti-glycation
activities that are used in diabetes, nephritis, or hyperten-
sion therapy [3]. In terms of chemical constituents related
to these bio-activities, flavonoids such as luteolin, formo-
nonetin and apigenin are identified from Stigmata Maydis
and their antioxidant properties have been illustrated
[4–7]. Additionally, polysaccharides of Stigmata Maydis
have been shown to reduce blood glucose and protein
glycation in diabetic mice [8, 9].
Under physiological conditions, reactive oxygen spe-
cies (ROS) and protein glycation are important mole-
cules and essential biochemical events in the human
body. However, excessive ROS or accumulated advanced
glycation end-products (AGEs) may lead to tissue dam-
age and aging [10]. For instance, diabetes is a complex
metabolic disease with hyperglycaemia resulting from ei-
ther insulin deficiency (Type 1 diabetes) or impaired in-
sulin action and insulin secretory function (Type 2
diabetes) [11]. When diabetes is not well controlled,
chronic hyperglycaemia leads to the progression of vari-
ous diabetic complications via oxidative stress and AGE
formation [12].
The loss of β-cell function and mass observed in un-
controlled diabetes may also be owing to glucotoxicity.
Due to low levels of antioxidant enzymes, pancreatic β-
cells are susceptible to oxidative stress via the produc-
tion of excessive ROS under hyperglycaemic conditions
[13]. As a result, glucotoxicity causes insulin secretory
dysfunction and increased β-cell apoptosis, thus initiat-
ing a vicious cycle for glycaemic control [14, 15]. More-
over, low-level inflammation and additional oxidative
stress from AGEs may affect β-cell proliferation and sur-
vival, thereby promoting β-cell failure [16].
Using corn silk constituents that possess both antioxi-
dant and anti-glycation bio-activities, we aimed to gener-
ate a corn silk extract fraction that combines both
activities to provide protective effects against glucotoxi-
city in insulin-secreting cells.
Methods
Extraction and partition of Stigmata Maydis
Stigmata Maydis was purchased from a Fu-Ji Chinese
Traditional Medicine Store in Taipei on November 2008.
Voucher specimens were deposited with the Herbarium
of the National Research Institute of Chinese Medicine
(NHP-00351). The ethanol extract (YMS) was made by
extracting the dried material of Stigmata Maydis (6 kg)
with 100 L of 95 % ethanol at 55 °C for 7 h. Each frac-
tion was made by partitioning the water suspended YMS
(135 g) with corresponding solvents, such as n-hexane
(Hex), ethyl acetate (EA), n-butanol (BuOH), to yield
YMS-Hex, −BuOH, −EA, and -W fractions, respectively
(Fig. 1a). Each YMS fraction and three flavonoid com-
pounds, including apigenin (A), formononetin (F), and
luteolin (L), were applied on a Merck thin-layer chroma-
tography plate (Silica gel 60 F254, 0.25 mm) (Darmstadt,
Germany) under the development in a mobile phase of
CHCl3 and MeOH (8.5:1.5). Afterwards, separated spots
were sprayed with anisaldehyde spray reagent and de-
tected after ultraviolet absorption at 254 nm and 365 nm.
b
a
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Fig. 1 Four YMS Fractions (YMS-Hex, −BuOH, −EA, −W) partitioned
from the ethanol extract of Stigmata Maydis (YMS) with chemical
characterisation by thin-layer chromatography (TLC). a The scheme
of the preparation process for four YMS fractions from corn silk
(Stigmata Maydis) crude extract. The estimated dry weight and yield
of each fraction (except for YMS-W) are listed in parentheses. b A
representative TLC chromatography of mixed sample (Mix; lane 1),
four YMS fractions (−Hex, −EA, −BuOH, −W; lane 2–5), and three
flavonoid compounds (apigenin, formononetin, luteolin; lane 6–8)
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ABTS free radical scavenging assay
2,2′-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid)
(ABTS) was used for the measurement of antioxidant ac-
tivity. Briefly, a reaction mix consisting of potassium per-
sulfate (2.45 mM) in ABTS solution (7 mM) was
prepared and kept in the dark at room temperature for
at least 16 h before use. The intensively-coloured
ABTS˙+ solution was then diluted with 0.01 M phos-
phate buffered saline (PBS) to give a pH of 7.4 with an
absorbance of 0.70 at 734 nm. The Stigmata Maydis
fractions were diluted 100× with the ABTS˙+ solution to
a total volume of 1 ml. Absorbance was measured at
6 min after the addition of test reagents. A negative con-
trol was made with PBS instead of ABTS˙+ solution. The
% inhibitions by different concentrations of samples
were calculated according to the following equation:
½1−ðAbssampleþ ABTS˙þsolution= AbsABTS˙þsolutionÞ  100 [17].
Bovine serum albumin (BSA)-methylglyoxal (MG) assay
and AGE preparation
This assay was used to evaluate protein glycation, and
BSA fluorescence levels were measured. Briefly, BSA
(10 mg/ml) was non-enzymatically glycated via incu-
bation in 1 M PBS, pH 7.4, at 37 °C for 7 days in the
presence of 1 mM MG and 3 mM sodium azide. The
Stigmata Maydis fractions were tested at concentra-
tions of 0.01, 0.02, 0.05, 0.1, and 1.0 mg/ml. Fluores-
cence of the samples was measured at the excitation
and emission wavelengths of 335 and 385 nm, re-
spectively, versus a blank containing the protein and
MG. The % inhibition by different concentrations of sam-
ples was calculated according to the following equation:
[1− (Fsample +BSA+ glucose ‐ Fsample + BSA/ FBSA+ glucose ‐ FBSA)] ×
100. Aminoguanidine (AG) was used as a positive control.
The reactant under control condition was collected to
generate AGEs through the dialysis and lyophilisation
process. Products were kept at −80 °C for cell-based
studies.
Cell culture
The clonal rat pancreatic β-cell line (BRIN-BD11) was
kindly provided by prof. PR Flatt at Univiersity of Ulster,
Coleraine, UK and routinely grown as a monolayer in
culture dishes at 37 °C under 5 % CO2/air with 90 % hu-
midity. Cells were maintained in RPMI 1640 medium
containing 10 % foetal bovine serum and 5 % penicillin
and streptomycin mixture.
Cell viability assay (neutral red)
The cell viability assay was performed as previously de-
scribed [18]. Briefly, at the end of cell treatments, the
medium was replaced with the neutral red solution and
incubated for another 2 h. Quantification of the uptake
of the neutral red by functional lysosomes in cells was
spectrophotometrically measured at 540 nm.
Cell proliferation assay (WST-1)
The WST-1 cell proliferation assay was performed ac-
cording to the manufacture’s protocol (Cayman Chem-
ical). Briefly, cells were seeded on 96-well plates and the
culture medium was replaced with various conditioned
medium for 48 h. At the end of treatment, the WST-1
reagent was added and incubated for another 2 h.
Finally, the plate was directly measured for absorbance
at 450 nm.
Spectrofluorometric measurement of intracellular ROS
Intracellular ROS were measured by the CM-
H2DCFDA assay. Cells were cultured at 37 °C with
various conditions which were described in figure
legends. After 24 h, medium was replaced with the
peroxide sensitive fluorescent probe, 5,6-dicarboxy-
2,7-dichlorodihydro fluorescein diacetate (carboxy-
H2DCFDA; 20 μM), for an additional 30 min at 37 °C.
The cells were then solubilised with 1 % SDS and 5 mM
Tris HCl (pH 7.4). The fluorescence intensity of the lysate
was determined using a spectrofluorometer with excita-
tion and emission wavelengths of 495 nm and 517 nm,
respectively.
Flow cytometry with annexin V/Propidium iodide (PI)
staining
BRIN-BD11 cells were treated as mentioned above.
Afterwards, they were trypsinised, pelleted, and resus-
pended in culture medium at a concentration of 1 ×
106 cells/ml. After transferring 0.5 ml of the cell sus-
pension to a new tube, 10 μl media binding reagent
and 1.25 μl annexin V-FITC were added. Following
gentle vortexing, the mixture was incubated for
15 min at room temperature in the dark. After centri-
fuging at 1000xg for 5 min at room temperature,
media was removed and 0.5 ml of cold 1× binding
buffer and 10 μl propidium iodide were added.
Following gentle vortexing, the sample was analysed
on the flow cytometer within a 1 h period. The per-
centages of apoptotic and necrotic cells for each sam-
ple were estimated [19].
Gene expression analysis
BRIN-BD11 cells were seeded on 6 cm-dish (5 × 105
cells/dish) and cultured under the condition described
in Figure legends. At the end of experiments, total
RNA were extracted and reverse transcribed. 50 ng of
complementary (c)DNA of each sample was used for
later polymerase chain reaction (PCR). Respective pri-
mer sequence, annealing temperature, and size of
PCR product of each gene was listed below. Beta-
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actin: For 5′-CGTAAAGACCTCTATGCCAA-3′ and
Rev 5′-AGCCATGCCAAATGTGTCAT-3′; 57 °C;
349b.p. Glucokinase: For 5′-AAGGGAACTACATCG
TAGGA-3′ and Rev 5′-CATTGGCGGTCTTCATAGTA-
3′; 57 °C; 130b.p. pancreatic and duodenal homeobox-1
(PDX-1): For 5′-CTCGCTGGGAACGCTGGAACA-3′
and Rev 5′-GCTTTGGTGGATTTCATCCACGG-3′;
55 °C; 225b.p. Insulin: For 5′-TGCCCAGGCTTTTGT
CAAACAGCACCTT-3′ and Rev 5′-CTCCAGTGC
CAAGGTCTGAA-3′; 52 °C; 187b.p. PCR products were
separated by ethidium bromide stained gel electrophor-
esis, visualized, photographed with a digital camera, and
quantified with Genetools 3.06 (Syngene, Frederick, MD,
USA) [20].
Insulin secretion
BRIN-BD11 cells were plated on 24-well plates (0.5 × 105
cells/well) and incubated for 48 h with media containing
5.6 or 30.0 mM glucose. Then, after 1 h of pre-
incubation with 1.1 mM glucose, cells were challenged
either with 1.1 mM or with 16.7 mM glucose in Krebs-
Ringer Bicarbonate Buffer for 20 min. The media were
collected for insulin determination. Insulin concentra-
tions were quantified by the Homogeneous Time-
Resolved Fluorescence (HTRF) insulin assay and
normalized to a million of total cell numbers [21].
Statistical analysis
Data were presented as mean ± standard error of the
mean. Statistical analyses were performed using Graph-
Pad Prism (GraphPad, CA, USA). Single parameter-
based comparisons were obtained from the unpaired
student’s t-test. P values less than 0.05 and 0.01 were
considered to be significant. Multiparametric compari-
sons were performed using one-way ANOVA, followed
by post-hoc analyses by Tukey’s HSD protected least sig-
nificant difference.
Results
Chemical characterization of four YMS fractions
partitioned from an ethanolic crude extract of corn silk
As shown in Fig. 1b, all fractions and the three flavonoid
compounds were individually developed on a single TLC
plate. In addition, all samples were pooled and co-
spotted on the same position on the 1st lane (Mix). Ac-
cording the polarity of the solvents for extraction, the Rf
values of all the detected compounds were distributed
among the ranges of Hex (0.71 to 0.91), EA (0.52–0.71),
BuOH (0.01 to 0.52) and H2O (0.0 to 0.01) fractions.
The Rf values for two (apigenin and luteolin) of the three
flavonoid compounds (apigenin: 0.66; formononetin:
0.74; luteolin: 0.57) were in the range of the YMS-EA
fraction.
The ethyl acetate fraction (YMS-EA) most potently
scavenges free radicals in vitro and protects against
effects of H2O2 on β-cells
All fractions exhibited dose-dependent free radical scav-
enging effects (Fig. 1a). However, the effect of YMS-EA
was superior to that of YMS-Hex, −BuOH, and -W (p <
0.001), as it provided 75 % inhibition at a concentration
of 100 μg/ml. Therefore, we chose YMS-EA as the major
fraction and compared its effects with those of other test
agents. First, to compare the protective effects of YMS
fractions and reference drugs on H2O2-mediated ROS
production and β-cell death, BRIN-BD11 cells were
treated with H2O2 (125 μM) in the presence of YMS
fractions (100 μg/ml), AG (2 mM), metformin (Met;
100 μM), or trolox (Trox; 100 μM) for 24 h.
As shown in Fig. 2b, there is nearly a three-fold in-
crease in ROS levels in H2O2-treated BRIN-BD11 cells.
The presence of YMS-EA significantly decreased ROS
levels in H2O2-treated BRIN-BD11 cells. Comparing
YMS-EA with other test agents, only YMS-Hex, YMS-
W, and Trox exhibited similar activities. In addition,
there was a 50 % reduction in the viability of H2O2-
treated BRIN-BD11 cells after 24 h (Fig. 2c). YMS-EA
significantly improved the cell viability of H2O2-treated
BRIN-BD11 cells. YMS-Hex, YMS-W, AG, Met, and
Trox provided similar protective effects.
YMS-EA and reference drugs attenuate the effects of
acute H2O2 treatment on proliferation in BRIN-BD11 cells
In terms of the impact of acute H2O2 treatment on cell
proliferation, BRIN-BD11 cells were transiently treated
with H2O2 for 2 h, and proliferation was monitored at
24 h post-treatment. The cell proliferation rate of BRIN-
BD11 cells treated with H2O2 (125 or 250 μM) dropped
over 50 % at 6 h post-treatment (Fig. 3a). At 24 h post-
treatment, the cell proliferation ratio of BRIN-BD11 cells
that were treated with the lower concentration of H2O2
(125 μM) returned to original levels. After 48 h, there
was a 50 % reduction in the proliferation of BRIN-BD11
cells that were treated with higher concentration of
H2O2 (250 μM). Therefore, the effects of YMS-EA and
reference drugs were tested in the presence of
250 μM H2O2 .
After acute H2O2 challenge, the treatment with YMS-
EA or reference drugs insufficiently improved cell prolif-
eration (Fig. 3b). YMS-EA had a better effect at 50 μg/
ml compare with that at 100 μg/ml. However, all of the
reference drugs performed better than 100 μg/ml YMS-
EA (p < 0.001).
According to the cell death analysis, the transient
treatment of BRIN-BD11 cells with H2O2 for 2 h for
BRIN-BD11 cells caused late apoptosis in a dose-
dependent manner at 24 h post-treatment. The apop-
totic cell population reached 70 % after 24 h when
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BRIN-BD11 cells were transiently challenged with
250 μM H2O2 (Fig. 3c). Under this condition, treatment
with YMS-EA or reference drugs had no effect (Fig. 3d).
YMS-EA treatment ameliorates MG-mediated glycation,
ROS production, and cell death
The anti-glycation activity was determined by the pro-
duction efficiency of fluorescent AGEs, which were gen-
erated by co-incubating BSA and MG (Fig. 4a). All YMS
fractions inhibited the formation of AGEs in a dose-
dependent manner. At low concentrations (10 μg/ml),
the inhibitory effect of YMS-EA was less effective than
that of YMS-Hex and -BuOH. However, at high concen-
trations (1000 μg/ml), YMS-EA demonstrated the most
effective anti-glycation activity when compared with
YMS-Hex, −BuOH, and -W (p < 0.01, p < 0.001, and p <
0.001, respectively).
As shown in Fig. 4b, MG (800 μM)-treated BRIN-
BD11 cells exhibited three-fold increase in ROS levels
after 24 h. Treatment with 100 μg/ml YMS-EA signifi-
cantly reduced ROS production. Similar effects were ob-
served with YMS-W, Met, and Trox. AG appeared to be
the most potent anti-glycation agent. Furthermore, after
BRIN-BD11 cells were treated with 800 μM MG for
24 h, viability decreased by nearly 50 % (Fig. 4c). In the
presence of YMS-EA, there was a significant increase in
the viability of BRIN-BD11 cells. Similar effects were ob-
served with YMS-W, Met, and Trox. It is important to
note that AG treatment elicited a nearly 100 % protect-
ive effect in BRIN-BD11 cells.
YMS-EA treatment has no protective effects on AGE-
mediated cell death and anti-proliferation in BRIN-BD11
cells
The presence of AGEs (3 mg/ml) in the culture
medium significantly reduced viability at 48 h post-
treatment (p < 0.05) (Fig. 5a). There was no differ-
ence in cell viability under this condition in the
presence of YMS-EA (50 or 100 μg/ml). Addition-
ally, treatment with 3 mg/ml AGEs had a potent
anti-proliferation effect on BRIN-BD11 cells (p <
0.001). Surprisingly, instead of providing beneficial
effects on cell proliferation, the presence of YMS-EA
(100 μg/ml) significantly worsened cell proliferation
(p < 0.05).
Addition of YMS-EA attenuates the hyperglycaemia-
induced elevation of ROS, reduction of β-cell marker
genes, and impairment of glucose responsiveness in
BRIN-BD11 cells
Compared with cells cultured under 5.6 mM glucose,
cells cultured under 30 mM glucose exhibited a 1.5-fold
increase in ROS levels (Fig. 6a). The presence of YMS-
EA significantly suppressed the induction of ROS by
Fig. 2 Comparison of YMS fractions and reference drugs for bio-
activities against ABTS- and H2O2-mediated free radical generation
and H2O2- induced cell death. a Free radical scavenging activities of
YMS fractions. Data are mean ± standard error of the mean
(SEM); n = 3. cp < 0.001 versus the corresponding YMS-EA group.
b Inhibitory effects of YMS fractions (100 μg/ml), aminoguanidine
(AG; 2 mM), metformin (Met; 100 μM), and trolox (Trox; 100 μM)
on H2O2 (125 μM)-induced ROS levels in BRIN-BD11 cells after
24 h. Data are mean ± SEM (n = 5). ap < 0.05, bp < 0.01, cp < 0.001
versus the YMS-EA group. c Viability of BRIN-BD11 cells that were
treated with H2O2 (125 μM) for 24 h in the presence of YMS
fractions, AG, Met, and Trox. Data are mean ± SEM (n = 5). bp <
0.01 and cp < 0.001 versus the YMS-EA group
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30 mM glucose (p <0.01). Both concentrations of YMS-
EA were equally effective, whereas none of the reference
drugs had ROS scavenging effects.
We further analysed the gene expression of β-cell
markers in the presence of 5.6 mM or 30 mM glucose.
There was a significant reduction in the mRNA levels of
insulin, glucokinase, and pancreatic and duodenal
homeobox-1 (PDX-1) (Fig. 6b). Consistently, the pres-
ence of YMS-EA attenuated this reduction in the mRNA
levels of β-cell markers.
Finally, when BRIN-BD11 cells were cultured under
30 mM glucose for 48 h, the glucose responsiveness of
BRIN-BD11 cells was abolished (Fig. 6c). Treatment of
50 μg/ml YMS-EA restored insulin secretory activity in
response to 16 mM glucose (p < 0.01). However, this
beneficial effect did not appear when 100 μg/ml YMS-
EA was used. Under the stimulated condition (16.7 mM
glucose), the amount of insulin secreted from YMS-EA
(50 μg/ml)-treated BRIN-BD11 cells was significantly
more (p <0.01) than that from YMS-EA (100 μg/ml)-
treated cells. In contrast, in Fig. 6d, treatment of AG
could only significantly enhanced insulin secretion under
basal condition (p <0.05) rather than stimulated
condition.
Fig. 3 Evaluation of YMS-EA and reference drugs against acute H2O2 challenge mediated anti-proliferation and apoptosis in BRIN-BD11 cells. a
BRIN-BD11 cells were treated with H2O2 for 2 h, and then the medium was replaced with culture medium. The cell proliferation assay (WST-1)
was performed at 0, 6, 12, 24, 36, and 48 h. Data are mean ± SEM (n = 8). ap < 0.05, bp < 0.01, cp < 0.001 versus time 0. b Cell proliferation activity
at the end of 48 h in the culture medium with YMS-EA (100 μg/ml), AG (2 mM), Met (100 μM) or Trox (100 μM) after acute H2O2 (250 μM) challenge.
Data are mean ± SEM (n = 8). ap < 0.05, bp < 0.01, cp < 0.001 versus no treatment after H2O2 challenge. c The population of necrotic or apoptotic cells
was evaluated at 24 h after acute H2O2 (250 μM) challenge. Data are mean ± SEM (n = 4). bp < 0.01, cp < 0.001 versus the corresponding population
with no treatment after H2O2 challenge. d Apoptotic cell population in the presence of test agents at 24 h after H2O2 (250 μM) challenge. Data are
mean ± SEM (n = 4)
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Individual effects of three flavonoid compounds on dual
activities and beta-cell protection
By employing previous experiments, individual effects of
apigenin (A), formononetin (F) and luteolin (L) were ex-
amined. In Fig. 7a, only apigenin and luteolin provided a
dose-dependent protective effect on H2O2 –induced
bête-cell death. In terms of anti-AGE formation, only
apigenin at 100 μM can significantly inhibited AGE for-
mation (p <0.01). Furthermore, three flavonoids pro-
vided beta-cell protection against methylglyoxal.
Formononetin appeared to be superior to other two
(Fig. 7c). In terms of AGEs-inhibited cell proliferation,
all flavonoids could provide beneficial effects. Instead,
addition of apigenin and luteolin worsen the inhibitory
effects of AGEs on cell proliferation. Finally, impaired
glucose-responsiveness of hyperglycemia-damaged
BRIN-BD11 cells was unable to be restored by three
Fig. 4 Comparison of YMS fractions and reference drugs for bio-
activities against methylglyoxal-mediated in vitro glycation, ROS
elevation, and viability reduction. a Anti-glycation activities of
YMS fractions (100 μg/ml), AG (2 mM), Met (100 μg/ml), and
Trox (100 μg/ml). Data are mean ± SEM; n = 3. ap < 0.05, bp < 0.01,
cp < 0.001 versus the corresponding YMS-EA group. b Inhibitory
effects of YMS fractions and reference drugs on methylglyoxal
(800 μM)-induced reactive oxygen species (ROS) levels after 24 h.
Data are mean ± SEM (n = 5). cp < 0.001 versus the YMS-EA group.
c Protective effects of YMS fractions and reference drugs on
methylglyoxal (800 μM)-mediated cell death after 24 h. Data are
mean ± SEM (n = 5). cp < 0.001 versus the YMS-EA group
Fig. 5 Advanced glycation end product (AGE)-mediated cell death
and anti-proliferation effects on BRIN-BD11 cells were unaffected by
YMS-EA treatment. Effects of a 48-h cell culture with AGEs on cell
viability (a) and proliferation (b) in the presence or absence of Y2S-
EA were measured. Data are mean ± SEM (n = 8). ***p < 0.001 versus
the BSA group
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flavonoids (Fig. 7d). However, addition of formononetin
partially increased basal insulin secretion (Fig. 7e).
Discussion
Because a large amount of corn silk is treated as agricul-
ture waste after the processing of corn, using a simple
preparation process to develop a corn silk fraction with
health benefits would promote the utilization of corn
silk. In the present study, we aimed to make a fraction
with dual bio-activities, including antioxidant and anti-
glycation activities. Aminoguanidine, trolox, and metfor-
min are three reference drugs with single or dual
activities against oxidative stress and glycation [22–25].
Our in vitro results indicate that the YMS-EA fraction
was the most effective fraction. Although the YMS-
BuOH fraction was partitioned with n-butanol, which
has the closest polarity index number compared to ethyl
acetate, it exhibited significantly less bio-activity. The Rf
values of apigenin and luteolin were in the range of
YMS-EA suggested that both flavonoids may contribute
to the dual bioactivity of YMS-EA. Luteolin derivatives
were also previously identified from EA fraction [3].
Interestingly, two independent research publications
showing that apigenin has activity to scavenge ROS and
luteolin intervenes the formation of AGEs support our
view [6, 26].
The islets are known to have relatively low levels of
antioxidants, and decreases in blood glutathione levels
contribute to the accumulation of ROS in the islet dur-
ing diabetes. Thus, the application of an antioxidation
mechanism to protect beta-cell survival and function is
a long-accepted concept [27]. The employment of anti-
oxidants is an important strategy for the preservation of
β-cell function, as shown in several experimental and
clinical studies [28, 29]. Consistent with the above con-
cept, our results demonstrate that YMS-EA possessed
Fig. 6 Beneficial effects of YMS-EA on BRIN-BD11 cells in a high-glucose (30 mM) medium induced the generation of free radicals, the reduction
of β-cell marker genes, and the impairment of glucose-induced insulin secretion. a Effects of YMS-EA, AG (2 mM), and Met (100 μM) on ROS levels
in BRIN-BD11 cells cultured in high-glucose medium for 48 h. Data are mean ± SEM (n = 6). ap < 0.05 and bp < 0.01 versus the YMS-EA (100 μg/ml)
group. b Effects of YMS-EA on the gene expression of insulin/glucokinase/ pancreatic and duodenal homeobox-1 (PDX-1) in BRIN-BD11 cells
cultured in high-glucose medium for 48 h. Data are mean ± SEM (n = 4). *p < 0.05 and **p < 0.01 versus the control culture condition (5.6 mM
glucose). c Effects of YMS-EA on the glucose-responsiveness of BRIN-BD11 cells cultured in high-glucose medium for 48 h. Data are mean ± SEM
(n = 8). **p < 0.01 versus the 1.1 mM glucose group-under the same culture condition. bp < 0.01 versus the corresponding YMS-EA (100 μg/ml)
group. d Effects of AG and Met on the glucose-responsiveness of BRIN-BD11 cells cultured in high-glucose medium for 48 h. Data are mean ±
SEM (n = 6). **p < 0.01 versus the 1.1 mM glucose group-under the same culture condition. ap < 0.05 versus the corresponding condition of None
(30 mM Glucose) group
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free radical scavenging activity and improved BRIN-
BD11 cell viability by reducing ROS production in the
presence of H2O2. This activity of YMS-1 was better
than that of YMS-BuOH, AG, and Met. In addition,
YMS-EA attenuated the anti-proliferative effect of acute
H2O2 treatment on BRIN-BD11 cells. However, the ap-
plication of reference drugs appeared to be more effect-
ive than YMS-EA. In contrast, the presence of YMS-EA
and other reference drugs could not effectively prevent
BRIN-BD11 cells from previously triggered apoptosis by
H2O2. Therefore, the present study suggests that YMS-
EA and reference drugs are more suitable for the
prevention or intervention of ROS-induced cell death.
Similar to reference drugs, YMS-EA could not rescue
H2O2-induced apoptotic cells. This was possibly because
YMS-EA and reference drugs lack of the DNA repair ac-
tivity against H2O2-induced DNA damages and subse-
quent apoptosis [20, 30].
AGEs are generated from the nonenzymatic inter-
action between protein and carbohydrates and are
regarded as important mediators of diabetes-related
complications. AGEs also play a role in beta-cell failure
in diabetes [16]. MG is a reactive compound that is de-
rived from glucose and fructose metabolism. It is not
only is a ROS donor but plays a role in AGE formation
[31]. In the current study, a high concentration of YMS-
EA was the most effective at inhibiting MG-mediated
AGE formation. However, only YMS-EA and YMS-W
significantly inhibited MG-induced ROS production and
improved cell survival in BRIN-BD11 cells. Among all
test agents, AG was the most potent agent for the pre-
vention of MG-mediated cell death. Our results also fur-
ther indicate that YMS-EA could not provide any
protection to enable β-cell survival against AGE-
mediated toxicity. Our findings suggest that YMS-EA
has a preventive, but not rescue, effect on the loss of β-
cell mass and function in diabetes.
Finally, we evaluated whether YMS-EA could prevent
glucotoxicity-induced β-cell dysfunction. The excessive
entry of glucose has been shown to elicit β-cell injury
Fig. 7 Evaluation of dual activities and beta-cell protective effects of three flavonoids. To explore the activity relationship between YMS-EA and
three flavonoids, we repeated following experiments by using three flavonoids (μM). a H2O2- induced cell death. Data are mean ± SEM (n = 6).
***p < 0.001 versus the None group. b AGE formation assay. Data are mean ± SEM (n = 3). ***p < 0.001 versus the None group. c Methylglyoxal-
induced cell death. Data are mean ± SEM (n = 12). *p < 0.05 and ***p < 0.001 versus the None group. d AGEs inhibited cell proliferation assay. Data
are mean ± SEM (n = 8). ***p < 0.001 versus the None group. e Glucose stimulated insulin secretion of hyperglycemia damaged cells. Data are
mean ± SEM (n = 6). **p < 0.01 versus the 1.1 mM glucose group-under the same culture condition. ap < 0.05 and cp < 0.001 versus the corresponding
condition of None (30 mM Glucose) group
Chang et al. BMC Complementary and Alternative Medicine  (2016) 16:432 Page 9 of 11
and increase the nonenzymatic glycation of cellular pro-
teins in animal studies [32, 33]. A β-cell line cultured
under high-glucose concentrations exhibits deteriorating
outcomes in insulin, glucokinase, and PDX-1 expression
[34–37]. Oxidative stress is also known to play an im-
portant role in high glucose-mediated β-cell dysfunction
[38]. Interestingly, only YMS-EA could effectively reduce
the level of ROS under high-glucose conditions. Such ef-
fect was associated with the restoration of the expression
of important beta-cell marker genes. However, in terms
of the insulin secretory function in response to glucose,
the improvement in glucose responsiveness by 50 μg/ml
YMS-EA treatment disappeared when 100 μg/ml YMS-
EA was used. In the future, an optimized dosage for
YMS-EA should be carefully examined.
By examining activities of three flavonoids, results ac-
tually pointed out similarity between the actions of three
flavonoids and YMS-EA. Consistent with the indication
that YMS-EA might contain apigenin and luteolin type
of flavonoids, both compounds provided strong anti-
oxidant effects while apigenin could also prevent AGE
formation. Interestingly, apigenin, luteolin, and YMS-EA
at high dose worsen AGEs-inhibited cell proliferation.
As a result, the dual effects of YMS-EA might be derived
from collaboration of those compounds.
Conclusions
In conclusion, our study provides some basis to support
the notion that Stigmata Maydis could be developed as a
dietary agent to protect β-cell survival and function
against pathological oxidative stress and protein glyca-
tion in diabetes.
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